Evidence map›Paper›PMID 24918341›Full record

ArticleExperimental neurology2014

Intrathecal infusion of BMAA induces selective motor neuron damage and astrogliosis in the ventral horn of the spinal cord.

Hong Z Yin, Stephen Yu, Cheng-I Hsu, Joe Liu, Allan Acab, Richard Wu, Anna Tao, Benjamin J Chiang, John H Weiss

Abstract read
In one paragraph

Article in Experimental neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Environmental Neurotoxin β-Microorganisms · 2022
    Review
  7. Review
  8. Review
  9. Modelling amyotrophic lateral sclerosis in rodents.Nature reviews. Neuroscience · 2022
    Review
  10. Review
  11. Article
  12. Cyanobacteria, Cyanotoxins, and Neurodegenerative Diseases:International journal of molecular sciences · 2021
    Review
  13. Article
  14. BMAA, Neurodegeneration, and Neuroprotection.Neurotoxicity research · 2021
    Article
  15. l-Serine Reduces Spinal Cord Pathology in a Vervet Model of Preclinical ALS/MND.Journal of neuropathology and experimental neurology · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Hong Z YinDepartment of Neurology, University of CA, Irvine, USA.
Stephen YuDepartment of Neurology, University of CA, Irvine, USA.
Cheng-I HsuDepartment of Neurology, University of CA, Irvine, USA.
Joe LiuDepartment of Neurology, University of CA, Irvine, USA.
Allan AcabDepartment of Neurology, University of CA, Irvine, USA.
Richard WuDepartment of Neurology, University of CA, Irvine, USA.
Anna TaoDepartment of Neurology, University of CA, Irvine, USA.
Benjamin J ChiangDepartment of Neurology, University of CA, Irvine, USA.
John H WeissDepartment of Neurology, University of CA, Irvine, USA; Department of Anatomy & Neurobiology, University of CA, Irvine, USA. Electronic address: jweiss@uci.edu.
University of California, Irvine · US

Funding

AMPA/KAINATE RECEPTORS,FREE RADICALS,MOTOR NEURON INJURYR01NS036548 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI WEISS, JOHN H · 1999 to 2010
$2.3M
NINDS NIH HHS NS36548NINDS NIH HHS R01 NS036548
6 · The paper itself

Abstract

The neurotoxin beta-N-methylamino-l-alanine (BMAA) was first identified as a "toxin of interest" in regard to the amyotrophic lateral sclerosis-Parkinsonism Dementia Complex of Guam (ALS/PDC); studies in recent years highlighting widespread environmental sources of BMAA exposure and providing new clues to toxic mechanisms have suggested possible relevance to sporadic ALS as well. However, despite clear evidence of uptake into tissues and a range of toxic effects in cells and animals, an animal model in which BMAA induces a neurodegenerative picture resembling ALS is lacking, possibly in part reflecting limited understanding of critical factors pertaining to its absorption, biodistribution and metabolism. To bypass some of these issues and ensure delivery to a key site of disease pathology, we examined effects of prolonged (30day) intrathecal infusion in wild type (WT) rats, and rats harboring the familial ALS associated G93A SOD1 mutation, over an age range (80±2 to 110±2days) during which the G93A rats are developing disease pathology yet remain asymptomatic. The BMAA exposures induced changes that in many ways resemble those seen in the G93A rats, with degenerative changes in ventral horn motor neurons (MNs) with relatively little dorsal horn pathology, marked ventral horn astrogliosis and increased 3-nitrotyrosine labeling in and surrounding MNs, a loss of labeling for the astrocytic glutamate transporter, GLT-1, surrounding MNs, and mild accumulation and aggregation of TDP-43 in the cytosol of some injured and degenerating MNs. Thus, prolonged intrathecal infusion of BMAA can reproduce a picture in spinal cord incorporating many of the pathological hallmarks of diverse forms of human ALS, including substantial restriction of overt pathological changes to the ventral horn, consistent with the possibility that environmental BMAA exposure could be a risk factor and/or contributor to some human disease.

Indexed as

Amino Acids, DiaminoAmyotrophic Lateral SclerosisAnimalsAnterior Horn CellsCell SurvivalCyanobacteria ToxinsDisease Models, AnimalDNA-Binding ProteinsExcitatory Amino Acid AgonistsGene Expression RegulationGlial Fibrillary Acidic ProteinGliosisGlutamate Plasma Membrane Transport ProteinsHumansMaleRats3-nitrotyrosineAmino Acids, Diaminobeta-N-methylamino-L-alanineCyanobacteria ToxinsDNA-Binding ProteinsExcitatory Amino Acid AgonistsGlial Fibrillary Acidic ProteinGlutamate Plasma Membrane Transport ProteinsSOD1 G93A proteinSuperoxide DismutaseTyrosine

Identifiers

PMID24918341
PMCPMC4194249
OpenAlexW1993280802

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.